Biogen is one those companies, like Sanofi until its recent Bioverativ acquisition, that has real pressure to make a big acquisition. Now that the tax incentives to bring money over from abroad have been brought through, the pressure just ramped up for the biotech.
Not least, because of the aforementioned Sanofi deal and the Celgene deal that were also announced on the same day – the excitement around M&A potentially gearing up again has many people excited and that’s bound to have more eyes focused on the moves Biogen could make.
